|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table S2. Donor and Recipients characteristics, stratified by donor type and induction therapy** | | | | | | |
| Characteristics | | SCD+ATG(n=331) | SCD+ basiliximab (n=90) | ECD+ATG(n=93) | ECD+ basiliximab (n=27) | *P* |
| Donor characteristic | |  |  |  |  |  |
| Age (years) | | 39[28,45] | 41[34,45] | 55[52,59] | 56[52,59] | <0.001 |
| Female sex | | 45(14) | 19(21) | 12(13) | 8(30) | 0.078 |
| BMI (kg/m2) | | 22.45[21.23,24.15] | 23.41[21.17,25.56] | 23.74[22.14,25.84] | 23.25[22.17,24.69] | 0.065 |
| Cause of death | |  |  |  |  | 0.001 |
| Cerebrovascular accident | | 91(27) | 46(51) | 25(27) | 12(44) |  |
| Head trauma | | 215(65) | 33(37) | 61(66) | 11(41) |  |
| other | | 25(8) | 11(12) | 7(7) | 4(15) |  |
| Terminal serum creatinine (umol/l) | | 143[105,185] | 145[112.5,184.5] | 138[104,190] | 150[105,179] | 0.705 |
| Donor proteinuria level | |  |  |  |  | 0.003 |
| 0 | | 203(62) | 37(41) | 44(47) | 10(37) |  |
| 1+ | | 77(23) | 33(37) | 30(32) | 6(22) |  |
| 2+ | | 30(9) | 11(12) | 11(12) | 5(19) |  |
| 3+ | | 21(6) | 9(10) | 8(9) | 6(22) |  |
| Warm ischemia time (min) | |  |  |  |  | 0.001 |
| ≤18 min | | 256(77) | 62(69) | 46(49) | 19(70) |  |
| ＞18min | | 75(23) | 28(31) | 47(51) | 12(30) |  |
| Recipient characteristic | |  |  |  |  |  |
| Age | | 43[34,50] | 41[33.5,50] | 47[36,53.5] | 43[34,53] | 0.097 |
| Male sex | | 216(65) | 51(56) | 64(69) | 15(56) | 0.031 |
| BMI (kg/m2) | | 21.62[21.18,24.59] | 22.53[21.42,24.89] | 21.89[21.52,24.95] | 22.62[21.29,24.69] | 0.451 |
| Cause of ESRD | |  |  |  |  |  |
| Hypertension | | 69(21) | 17(19) | 20(22) | 6(22) | 0.999 |
| Diabetes | | 82(25) | 24(27) | 19(20) | 6(22) |  |
| GN | | 114(34) | 31(34) | 34(37) | 8(30) |  |
| PKD | | 36(11) | 9(10) | 11(12) | 3(11) |  |
| Others | | 30(9) | 9(10) | 9(9) | 4(15) |  |
| Mode of dialysis | |  |  |  |  | 0.001 |
| HD | | 295(89) | 65(72) | 86(92) | 20(74) |  |
| PD | | 36(11) | 25(28) | 7(8) | 7(26) |  |
| Dialysis duration, mo | | 12[7,24] | 12[8.5,22.5] | 12[8,24] | 12.23[9,24] | 0.540 |
| Cold ischemia time, h | | 4[2,6] | 5[3,6] | 5[2,6] | 5[2,8] | 0.713 |
| Number of HLA mismatches | |  |  |  |  | 0.504 |
| Level1 | | 258(78) | 69(77) | 72(77) | 25(92) |  |
| Level2 | | 37(11) | 14(16) | 12(13) | 1(4) |  |
| Level3 | | 36(11) | 7(7) | 9(10) | 1(4) |  |
| Panel active antibody | |  |  |  |  | 0.448 |
| Positive | | 31(9) | 10(11) | 8 (8) | 5(18) |  |
| Negative | | 300(91) | 80(89) | 85(92) | 22(82) |  |
| CNI | |  |  |  |  | 0.658 |
| Cyclosporin | | 104(31) | 24(27) | 27(29) | 6(22) |  |
| Tacrolimus | | 227(69) | 66(73) | 66(71) | 21(78) |  |
| Rejection | |  |  |  |  | 0.900 |
| Antibody mediated rejection | | 14(4) | 10(11) | 5(5) | 3(11) |  |
| T cell mediated rejection | | 12(4) | 9(10) | 3(3) | 4(15) |  |
| Infection | |  |  |  |  | 0.961 |
| Urinary tract infection | | 20(6) | 10(11) | 6(7) | 4(15) |  |
| Pneumonia | | 31(9) | 12(13) | 9(10) | 5(19) |  |
| Proteinuria rate 5-year posttransplantation | | 30(9) | 10(11) | 17(18) | 6(22) | 0.028 |
| Renal functions 5-year Posttransplantation | 108.2[90,136.8] | | 103.6[90,123.5] | 120[95.7,150] | 130[105,192] | 0.013 |
| Continuous variables according to the Shapiro test, if P>0.05 the data are expressed as mean±SD, otherwise data are expressed as median [P25,P75]; Categorical variables are described by numbers and percentages (%).  Continuous variables were compared using ANOVA or Kruskal-Wallis tests, categorical variables were compared using the χ2 test and Fisher’s exact test.  Abbreviation: DGF: delayed graft function; BMI: body mass index; ESRD: end-stage renal disease; GN: glomerulonephritis; PKD: polycystic kidney disease; HD: hemodialysis; PD: peritoneal dialysis; HLA: human leukocyte antigen; CNI: calcineurin inhibitor; ATG:Antithymocyte globulin. | | | | | | |